{{Rsnum
|rsid=7128311
|Gene=LOC645490
|Chromosome=11
|position=20540973
|Orientation=plus
|GMAF=0.1345
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 12.4 | 48.2 | 39.4
| JPT | 15.9 | 47.8 | 36.3
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 1.8 | 98.2
| CHB | 12.4 | 48.2 | 39.4
| CHD | 15.6 | 49.5 | 34.9
| GIH | 1.0 | 9.9 | 89.1
| LWK | 0.0 | 0.0 | 0.0
| MEX | 3.4 | 32.8 | 63.8
| MKK | 0.0 | 1.3 | 98.7
| TSI | 0.0 | 2.0 | 98.0
| HapMapRevision=28
}}
{{PMID Auto GWAS
|PMID=19176441
|Trait=Treatment response for acute lymphoblastic leukemia
|Title=Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
|RiskAllele=C
|Pval=0.000005
|OR=13.90
|ORtxt=[2.72-71.1]
|OA=1
}}

{{PharmGKB
|RSID=rs7128311
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. (Initial Sample Size: 487 children; Replication Sample Size: NR); (Region: 11p15.1; Reported Gene(s): intergenic; Risk Allele: rs7128311-C); (p-value= 0.000005).This variant is associated with Treatment response for acute lymphoblastic leukemia.
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740025
}}

{{PharmGKB
|RSID=rs7128311
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.03, combined P value= 4.95E-06. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470157
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7128311
|overall_frequency_n=117
|overall_frequency_d=128
|overall_frequency=0.914062
|n_genomes=54
|n_genomes_annotated=0
|n_haplomes=100
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}